TreatmentBrain Inflammation · Gene Therapy


Nature Medicine, November 1999 Volume 5 Number 11 pp 1256 - 1263. (Clinical Study)


Abstract

Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials

R. A. Dewey5, 6, G. Morrissey1, 6, C. M. Cowsill1, 6, D. Stone1, F. Bolognani1, N.J.F. Dodd2, T. D. Southgate1, D. Klatzmann3, H. Lassmann4, M.G. Castro1 & P.R. Löwenstein1

1. Molecular Medicine and Gene Therapy Unit, Room 1.302 Stopford Building, School of Medicine,University of Manchester, Oxford Road, Manchester M13 9PT, UK. 2. Department of Medical Biophysics, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK. 3. Laboratoire de Biologie et Therapeutique des Pathologies Immunitaires, Universitè Pierre et Marie Curie, CNRS, Hôpital de la Pitiè-Salpétrière, 83 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France. 4. Neurological Institute, University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria. 5. R.A.D present address: Department of Neuropathology, Institute of Psychiatry, Kings College London, DeCrespigny Park, Denmark Hill, London SE5 8AS, UK. 6. R.A.D., G.M. and C.M.C. contributed equally to this study. Correspondence should be addressed to P R Löwenstein. e-mail: lowenstein@man.ac.uk and M G Castro. e-mail: mcastro@fs1.scg.man.ac.ul

The long-term consequences of adenovirus-mediated conditional cytotoxic gene therapy for gliomas remain uncharacterized. 
We report here detection of active brain inflammation 3 months after successful inhibition of syngeneic glioma growth. 
The inflammatory infiltrate consisted of activated macrophages/microglia and astrocytes, and T lymphocytes positive for leucosyalin, CD3 and CD8, and included secondary demyelination. 
We detected strong widespread herpes simplex virus 1 thymidine kinase immunoreactivity and vector genomes throughout large areas of the brain. 
Thus, patient evaluation and the design of clinical trials in ongoing and future gene therapy for brain glioblastoma must address not only tumor-killing efficiency, but also long-term active brain inflammation, loss of myelin fibers and persistent transgene expression.

© 1999 Nature Publishing Group

Source: http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v5/n11/abs/nm1199_1256.html



 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
| BL Newsletter |
Children's Corner | E-mail Alerts | Journals | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP